Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $652 Billion
  • Q2 2025

Adar1 Capital Management, LLC has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $652 Billion distributed in 210 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Keros Therapeutics, Inc. with a value of $71.9B, Protagonist Therapeutics, Inc with a value of $52.4B, Ea Series Trust with a value of $38B, Zai Lab LTD with a value of $29.7B, and Abivax Sa with a value of $23.5B.

Examining the 13F form we can see an increase of $113B in the current position value, from $539B to 652B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $652 Billion
Healthcare: $418 Billion
ETFs: $56.4 Billion
Basic Materials: $135 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
-
$2.03 Billion 0.31% of portfolio
-
Q2 2025 New
$95.4M
$2.03 Billion 0.31% of portfolio
149,385
Q4 2024 Added 381.08%
Anteris Technologies Global
-
$2.01 Billion 0.31% of portfolio
-
Q2 2025 Reduced 68.33%
$7.73B
$1.92 Billion 0.29% of portfolio
15,000
Q2 2025 New
$2.19B
$1.8 Billion 0.28% of portfolio
67,813
Q2 2025 Added 14.14%
$64.3B
$1.76 Billion 0.27% of portfolio
3,361
Q2 2025 Added 146.95%
$2.16B
$1.77 Billion 0.27% of portfolio
33,143
Q2 2025 Reduced 53.41%
$1.28B
$1.69 Billion 0.26% of portfolio
170,000
Q1 2025 New
$451M
$1.71 Billion 0.26% of portfolio
207,818
Q2 2025 Reduced 40.68%
Oruka Therapeutics Inc
-
$1.6 Billion 0.25% of portfolio
-
Q2 2025 Added 7.53%
$311M
$1.62 Billion 0.25% of portfolio
34,314
Q2 2025 Added 532.63%
Kiniksa Pharmaceuticals Intl
-
$1.56 Billion 0.24% of portfolio
-
Q2 2025 Added 36.53%
$2.2B
$1.53 Billion 0.23% of portfolio
53,125
Q4 2024 Reduced 39.92%
$1B
$1.43 Billion 0.22% of portfolio
62,088
Q2 2025 Reduced 59.62%
Tectonic Therapeutic Inc
-
$1.46 Billion 0.22% of portfolio
-
Q2 2025 Added 17.41%
$1.94B
$1.41 Billion 0.22% of portfolio
39,677
Q2 2025 Reduced 74.74%
$114M
$1.34 Billion 0.21% of portfolio
249,646
Q2 2025 Reduced 61.1%
$5.1B
$1.29 Billion 0.2% of portfolio
45,000
Q2 2025 New
$760M
$1.26 Billion 0.19% of portfolio
250,000
Q1 2025 Added 290.22%
$2.22B
$1.19 Billion 0.18% of portfolio
35,900
Q2 2025 Added 28.67%
$1.24B
$1.17 Billion 0.18% of portfolio
57,466
Q2 2025 Added 293.6%
$2.93B
$1.13 Billion 0.17% of portfolio
24,082
Q2 2025 Reduced 88.41%
Zura Bio LTD
-
$1.05 Billion 0.16% of portfolio
-
Q2 2025 Reduced 64.39%
$72.1M
$1.06 Billion 0.16% of portfolio
916,183
Q2 2025 Added 526.74%
$1.01B
$1.07 Billion 0.16% of portfolio
25,000
Q2 2025 Added 212.5%
Cidara Therapeutics Inc
-
$1.05 Billion 0.16% of portfolio
-
Q2 2025 Added 2.79%
$4.33B
$963 Million 0.15% of portfolio
18,313
Q2 2025 Reduced 72.65%
$154B
$955 Million 0.15% of portfolio
39,400
Q2 2025 Reduced 4.02%
$323M
$957 Million 0.15% of portfolio
249,920
Q2 2025 Added 18.12%
$44.3B
$970 Million 0.15% of portfolio
1,759
Q2 2025 Added 193.17%
Best Spac I Acquisition Corp
-
$1 Billion 0.15% of portfolio
-
Q2 2025 New
$511M
$948 Million 0.15% of portfolio
128,767
Q2 2025 Reduced 58.91%
$3.73B
$919 Million 0.14% of portfolio
13,962
Q1 2025 Added 252.4%
$3.62B
$904 Million 0.14% of portfolio
11,842
Q2 2025 New
Tenax Therapeutics Inc
-
$896 Million 0.14% of portfolio
-
Q2 2025 Added 126.29%
$1.9B
$889 Million 0.14% of portfolio
40,000
Q1 2025 New
Keen Vision Acquisition Corp
-
$853 Million 0.13% of portfolio
-
Q2 2025 New
Vistagen Therapeutics Inc
-
$842 Million 0.13% of portfolio
-
Q1 2025 Added 246.42%
Korro Bio Inc
-
$859 Million 0.13% of portfolio
-
Q2 2025 Added 0.15%
$3.82B
$872 Million 0.13% of portfolio
55,200
Q2 2025 Reduced 1.95%
Apogee Therapeutics Inc
-
$785 Million 0.12% of portfolio
-
Q2 2025 Reduced 82.77%
Kala Bio Inc
-
$713 Million 0.11% of portfolio
-
Q2 2025 Reduced 49.88%
$211M
$687 Million 0.11% of portfolio
237,605
Q2 2025 New
$611M
$746 Million 0.11% of portfolio
114,814
Q2 2025 Added 397.03%
Contineum Therapeutics Inc
-
$662 Million 0.1% of portfolio
-
Q2 2025 Reduced 1.16%
Kezar Life Sciences Inc
-
$675 Million 0.1% of portfolio
-
Q4 2024 Reduced 88.99%
$703M
$675 Million 0.1% of portfolio
85,826
Q2 2025 Reduced 78.44%
$238M
$676 Million 0.1% of portfolio
275,800
Q2 2025 Added 14.06%
$23B
$641 Million 0.1% of portfolio
5,100
Q2 2025 Added 13.33%

Summary

  • Portfolio
  • No. of Stocks 210
  • Current Value $652 Billion
  • Prior Value $539 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 43 stocks
  • Additional Purchases 61 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 53 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email